Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00233506
Status:
COMPLETED
Last Update Posted:
2017-02-06
First Post:
2005-10-03
Brief Title:
A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated
Sponsor:
University of Iowa
Organization:
University of Iowa
Study Overview
Official Title:
A Dose-Finding Study of CpG 7909 in Previously Treated Chronic Lymphocytic Leukemia
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CpG has the potential to stimulate the immune system
this study will evaluate the safety of CpG given sub-q or IV
purpose is to measure biological changes in CLL cells after receiving CpG
this study will evaluate the safety of CpG given sub-q or IV
purpose is to measure biological changes in CLL cells after receiving CpG
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None